Agenus selected for late-breaking oral presentation at esmo-gi
Lexington, mass.--(business wire)--agenus (nasdaq: agen), a leading immuno-oncology company dedicated to developing innovative treatments for cancer and infectious diseases, today announced a data update on botensilimab (multifunctional ctla-4 antibody) in combination with balstilimab (pd-1 antibody) for patients with non-microsatellite instability-high metastatic colorectal cancer (non-msi-h mcrc) has been selected for a late-breaking oral presentation at the upcoming esmo world congress on gastrointestinal cancer (esmo gi), to be held june 28 – july 1, 2023 in barcelona, spain. presentation details: abstract title: results from an expanded phase 1 trial of botensilimab, a multifunctional anti-ctla-4, plus balstilimab (anti-pd-1) for metastatic heavily pretreated microsatellite stable colorectal cancer (nct03860272) abstract number: lba-4 presenting author: andrea j. bullock, md, mph, assistant professor of medicine, division of medical oncology, beth israel deaconess medical center presentation date and time: 6/30/2023, 6:00pm – 6:10pm cest data presented at the conference will be available to view in the publications section of the agenus website (https://agenusbio.com/publications) following the esmo gi conference. about botensilimab botensilimab is a novel, multifunctional ctla-4 investigational antibody that has been designed to extend clinical benefits to “cold” tumors that have not historically responded to standard of care or investigational therapies. in addition to binding to the ctla-4 receptor, its fc-enhanced structure induces a memory immune response, downregulates regulatory t cells, and delivers better priming and activation of t cells, thereby amplifying immune responses. in a phase 1b clinical study of more than 350 patients, botensilimab has demonstrated clinical responses in nine, previously io unresponsive, solid tumor cancers, either alone or in combination with agenus’ pd-1 antibody, balstilimab (data presented at asco gi 2023, sgo 2023, ctos 2022, sitc 2022). agenus is conducting global, randomized phase 2 trials in non-msi-h mcrc, melanoma, and pancreatic cancer as part of its activate trial programs. additional information about these botensilimab trials can be found at www.clinicaltrials.gov under the identifiers nct05608044, nct05630183, and nct05529316, respectively. a global phase 3 trial in non-msi-h mcrc is expected to launch in 2023. about agenus agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer and infections. the company's vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing combination approaches that leverage a broad repertoire of antibody therapeutics, adoptive cell therapies (through its subsidiary mink therapeutics), and adjuvants (through its subsidiary saponiqx). the company is equipped with a suite of antibody discovery platforms and a state-of-the-art gmp manufacturing facility with the capacity to support clinical programs. agenus is headquartered in lexington, ma. for more information, please visit www.agenusbio.com and our twitter handle @agenus_bio. information that may be important to investors will be routinely posted on our website and twitter. forward looking statements this press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements relating to the use of botensilimab and balstilimab, for instance, statements regarding therapeutic benefit and efficacy, mechanism of action (including validation of mechanism of action), potency, durability, and safety profile (including the absence of specific toxicities) of the company’s therapeutic candidates; and any other statements containing the words "may," "believes," "expects," "anticipates," "hopes," "intends," "plans," "forecasts," "estimates," "will," “establish,” “potential,” “superiority,” “best in class,” and similar expressions are intended to identify forward-looking statements. these forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. these risks and uncertainties include, among others, the factors described under the risk factors section of our most recent quarterly report on form 10-q or annual report on form 10-k filed with the securities and exchange commission. agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. these statements speak only as of the date of this press release, and agenus undertakes no obligation to update or revise the statements, other than to the extent required by law. all forward-looking statements are expressly qualified in their entirety by this cautionary statement.
